Andre von Bueren

Dr. Andre von Bueren

1. Cansearch Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, 1211 Geneva, Switzerland
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
BWBarbara C Worst
Barbara C Worst
CTCornelis M Van Tilburg
Cornelis M Van Tilburg
GBGnana Prakash Balasubramanian
Gnana Prakash Balasubramanian
PFPetra Fiesel
Petra Fiesel
RWRuth Witt
Ruth Witt
OWOlaf Witt
Olaf Witt

9 August 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CTCornelis M. van Tilburg
Cornelis M. van Tilburg
EPElke Pfaff
Elke Pfaff
KPKristian W. Pajtler
Kristian W. Pajtler
KLKarin Langenberg
Karin Langenberg
PFPetra Fiesel
Petra Fiesel
OWOlaf Witt
Olaf Witt
INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm. Mean turnaround time from sample receipt to report was 25.4 days. The highest target priority level was observed in 42 patients (8.1%). Of these, 20 patients received matched targeted treatment with a median progression-free survival of 204 days [95% confidence interval (CI), 99–not applicable], compared with 117 days (95% CI, 106–143; P = 0.011) in all other patients. The respective molecular targets were shown to be predictive for matched treatment response and not prognostic surrogates for improved outcome. Hereditary cancer predisposition syndromes were identified in 7.5% of patients, half of which were newly identified through the study. Integrated molecular analyses resulted in a change or refinement of diagnoses in 8.2% of cases. Significance: The pediatric precision oncology INFORM registry prospectively tested a target prioritization algorithm in a real-world, multinational setting and identified subgroups of patients benefiting from matched targeted treatment with improved progression-free survival, refinement of diagnosis, and identification of hereditary cancer predisposition syndromes. See related commentary by Eggermont et al., p. 2677 . This article is highlighted in the In This Issue feature, p. 2659

31 October 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MPMarkus Priller
Markus Priller
JPJulia Pöschl
Julia Pöschl
LALeticia Abrão
Leticia Abrão
Andre von BuerenAndre von Bueren
Andre von Bueren
YCYoon-Jae Cho
Yoon-Jae Cho
USUlrich Schüller
Ulrich Schüller
Purpose: The transcription factor Forkhead box M1 (FoxM1) is a key regulator of cell-cycle progression. It is involved in the development of multiple organs, and we have previously reported on its important role for the mitotic entry of cerebellar granule neuron precursors. Constitutive expression of FoxM1 is required for the growth of multiple cancer types. This study aimed to determine its role in medulloblastoma, the most frequent malignant brain tumor in childhood that can derive from cerebellar granule neuron precursors. Experimental Design: We evaluated the expression of FoxM1 together with its prognostic value in two independent series of human medulloblastoma samples using immunohistochemistry (n = 43) and gene expression arrays (n = 193). The functional impact of FoxM1 expression was characterized by knockdown experiments in four human medulloblastoma cell lines, and the thiazole antibiotic siomycin A was tested to downregulate FoxM1 and inhibit tumor cell growth. Results: FoxM1 was highly expressed in all subtypes of medulloblastoma. Importantly, expression levels of FoxM1 significantly correlated with unfavorable clinical outcome in univariate analysis (P = 0.0005), and FoxM1 was identified as an independent prognostic marker by multivariate analysis (P = 0.037). Knockdown of FoxM1 in medulloblastoma cell lines resulted in a significant decrease of cell viability which was caused by a failure in mitotic spindle formation and caspase-dependent mitotic catastrophe. Siomycin A significantly inhibited the expression of FoxM1 and the growth of medulloblastoma cells. Conclusions: FoxM1 may be used as an additional prognostic marker and may represent a potential novel target to treat patients suffering from medulloblastoma. Clin Cancer Res; 17(21); 6791–801. ©2011 AACR.

14 June 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MEMoatasem El-Ayadi
Moatasem El-Ayadi
MAMarc Ansari
Marc Ansari
DSDominik Sturm
Dominik Sturm
GGGerrit H. Gielen
Gerrit H. Gielen
MWMonika Warmuth-Metz
Monika Warmuth-Metz
Andre von BuerenAndre von Bueren
Andre von Bueren
In the past years, pediatric high-grade gliomas (HGG) have been the focus of several research articles and reviews, given the recent discoveries on the genetic and molecular levels pointing out a clinico-biological uniqueness of the pediatric population compared to their adult counterparts with HGG. On the other hand, there are only scarce data about HGG in very young children (below 3 years of age at diagnosis) due to their relatively low incidence. However, the few available data suggest further distinction of this very rare subgroup from older children and adults at several levels including their molecular and biological characteristics, their treatment management, as well as their outcome. This review summarizes and discusses the current available knowledge on the epidemiological, neuropathological, genetic and molecular data of this subpopulation. We discuss these findings and differences compared to older patients suffering from the same histologic disease. In addition, we highlight the particular clinical and neuro-radiological findings in this specific subgroup of patients as well as their current management approaches and treatment outcomes.

28 January 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MEMoatasem El‐Ayadi
Moatasem El‐Ayadi
MAMarc Ansari
Marc Ansari
CKCaspar D. Kühnöl
Caspar D. Kühnöl
ABAnne Bendel
Anne Bendel
DSDominik Sturm
Dominik Sturm
Andre von BuerenAndre von Bueren
Andre von Bueren

23 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HOHolger Ottensmeier
Holger Ottensmeier
PSPaul G Schlegel
Paul G Schlegel
MEMatthias Eyrich
Matthias Eyrich
JWJohannes E Wolff
Johannes E Wolff
BJBjörn-Ole Juhnke
Björn-Ole Juhnke
SRStefan Rutkowski
Stefan Rutkowski
Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German brain tumour trials HIT2000 and HIT-REZ2005. Testing was performed using the validated Wuerzburg Intelligence Diagnostics (WUEP-D), which includes Kaufman-Assessment-Battery, Coloured Progressive Matrices, Visual-Motor Integration, finger tapping “Speed”, and the Continuous Performance Test. Of 104 patients in 47 centres, 72 were eligible for analyses. We assessed whether IQ was impacted by disease extent, disease location, patient age, gender, age at surgery, and treatment (chemotherapy with our without craniospinal irradiation [CSI] or local radiotherapy [LRT]). Median age at surgery was 2.3 years. Testing was performed at a median of 4.9 years after surgery. Patients with infratentorial EPs (treated with LRT) scored highest in fluid intelligence (CPM 100.9±16.9, mean±SD); second best scores were achieved by patients with MB without metastasis treated with chemotherapy alone (CPM 93.9±13.2), followed by patients with supratentorial EPs treated with LRT. In contrast, lowest scores were achieved by patients that received chemotherapy and CSI, which included children with metastasised MB and those with relapsed MB M0 (CPM 71.7±8.0 and 73.2±21.8, respectively). Fine motor skills were reduced in all groups. Multivariable analysis revealed that type of treatment had an impact on IQ, but essentially not age at surgery, time since surgery or gender. Our results confirm previous reports on the detrimental effects of CSI in a larger cohort of children. Comparable IQ scores in children with MB treated only with chemotherapy and in children with EP suggest that this treatment strategy represents an attractive option for children who have a high chance to avoid application of CSI. Longitudinal follow-up examinations are warranted to assess long-term neuropsychological outcomes.